Extended-release intramuscular paliperidone palmitate: A review of its use in the treatment of schizophrenia

Drugs

Volumn 72, Issue 8, 2012, Pages 1137-1160

  Carter, Natalie J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Paliperidone; Schizophrenia

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; LEVODOPA; PALIPERIDONE; PROLACTIN; RISPERIDONE; SEROTONIN 2A RECEPTOR; SUSTENNA; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEART DISEASE; HUMAN; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TARDIVE DYSKINESIA; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MULTICENTER STUDIES AS TOPIC; PALMITATES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84861427207     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208640-000000000-00000     Document Type: Article

References (53)

1. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). National clinical guideline number 82 [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/ 11786/43607/43607.pdf [Accessed 2012 Jan 20]
2. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 Feb; 161 (2 Suppl.): 1-56
3. Auquier P, Lancon C, Rouillon F, et al. Mortality in schizophrenia. PharmacoepidemiolDrug Saf 2006 Oct; 15 (12): 873-9 (Pubitemid 44941640)
4. Robinson D, Woerner MG, Alvir JMJ, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56 (3): 241-7 (Pubitemid 29125132)
5. The Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study VIII. Five-year followup: clinical and psychosocial findings. Br J Psychiatry 1992 Oct; 161 (4): 496-500
6. Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev Recent Clin Trials 2012; 7 (1): 2-9
7. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007; 115: 260-7 (Pubitemid 46425751)
8. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry 2010; 71 Suppl. 2: 20-6
9. Janssen-Cilag International NV. Paliperidone palmitate 25, 50, 75, 100, and 150 mg prolonged-release suspension for injection (Xeplion): EU summary of product characteristics [online]. Available from URL: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002105/ WC500103317.pdf [Accessed 2011 Oct 6]
10. Ortho-McNeil-Janssen Pharmaceuticals. Paliperidone palmitate extended-release injectable suspension for intramuscular use (Invega Sustenna): US prescribing information [online]. Available from URL: http://www.accessdata. fda. gov/drugsatfda-docs/label/2011/022264s006lbl.pdf [Accessed 2012 Jan 10]
11. Janssen-Cilag International NV. Invega(paliperidone) prolonged-release tablets: EU summary of product characteristics [online]. Available from URL: http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000746/WC500034925.pdf [Accessed 2012 Jan 13]
12. Ortho-McNeil-Janssen Pharmaceuticals. Invega(paliperidone) extended-release tablets: US prescribing information [online]. Available from URL: http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/ 021999s020s024lbl.pdf [Accessed 2012 Jan 13]
13. Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 2010; 70 (10): 1295-317
14. Yang LP, Plosker GL. Paliperidone extended release. CNS Drugs 2007; 21 (5): 417-25; discussion 426-7 (Pubitemid 46698504)
15. Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry 2009; 195 (5 Suppl.): S13-9
16. Gopal S, Gassmann-Mayer C, Palumbo J, et al. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010; 26 (2): 377-87
17. European Medicines Agency. Paliperidone palmitate (Xeplion): European public assessment report [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Public-assessment-report/human/002105/ WC500103370.pdf [Accessed 2011 Oct 7]
18. European MedicinesAgency. Invega(paliperidone prolongedrelease tablets): scientific discussion [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/docu ment-library/EPAR-Scientific-Discussion/human/00074 6/WC500034928.pdf [Accessed 2012 Jan 9]
19. Karlsson P, Dencker E, Nyberg S, et al. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects: two open-label, single-dose studies [abstract no. PIII-57]. Clin Pharmacol Ther 2006 Feb; 79 (2): P74
20. Arakawa R, Ito H, Takano A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008 Apr; 197 (2): 229-35
21. Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64 (7): 701-23 (Pubitemid 38471372)
22. Gopal S, Hough DW, Xu H, et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010; 25 (5): 247-56
23. Nasrallah HA, Gopal S, Gassmann-Mayer C, et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 2010; 35 (10): 2072-82
24. Kramer M, Litman R, Hough D, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010; 13 (5): 635-47
25. Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010 Jun; 30 (3): 235-44
26. Pandina G, Lane R, Gopal S, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2011; 35 (1): 218-26
27. Schreiner A, Korcsog P, Niehaus D, et al. A prospective randomized controlled trial of paliperidone ER verus oral olanzapine in patients with schizophrenia [abstract]. Int Clin Psychopharmacol 2011 Sep; 26 e-Suppl. 1: e67-8
28. Luthringer R, Staner L, Noel N, et al. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 2007 Sep; 22 (5): 299-308 (Pubitemid 47237549)
29. Cleton A, Rossenu S, Hough D, et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles [abstract no. PI-74]. Clin Pharmacol Ther 2008 Mar; 83 Suppl. 1: S31
30. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, longacting formulation of an atypical antipsychotic. Clin Pharmacokinet 2009; 48 (9): 585-600
31. Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2011; 35 (4): 1002-8
32. Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010 Feb; 116 (2-3): 107-17
33. Fleischhacker WW, Gopal S, Lane R, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol 2012; 15 (1): 107-118. Plus supplementary material available from URL: http://journals.cambridge.org/action/dis playJournal?jid=PNP [Accessed 2012 Jan 17]
34. Bossie CA, Sliwa JK, Ma Y-W, et al. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry 2011 May 10; 11: 79
35. Alphs L, Bossie CA, Sliwa JK, et al. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann Gen Psychiatry 2011 Apr 11; 10: 12
36. Sliwa JK, Bossie CA, Ma Y-W, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr Res 2011; 132 (1): 28-34
37. Gopal S, Vijapurkar U, Lim P, et al. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol 2011; 25 (5): 685-97
38. Kozma CM, Slaton T, Dirani R, et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Curr Med Res Opin 2011; 27 (8): 1603-11
39. Gopal S, Pandina G, Lane R, et al. A post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov Clin Neurosci 2011 Aug; 8 (8): 26-33
40. Hough D, Lindenmayer J-P, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 2009; 33 (6): 1022-31
41. Alphs L, Gopal S, Karcher K, et al. Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases. Curr Drug Saf 2011; 6 (1): 43-5
42. Agid O, Foussias G, Remington G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010; 11 (14): 2301-17
43. Lundbeck Ltd. Depixol(flupentixol decanoate) injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/EMC/medicine/1074/SPC/Depixol+Injection+and+Conc+Injection/[Accessed 2012 Jan 17]
44. Sanofi-Aventis. Modecate(fluphenazine decanoate) concentrate injection 100mg/mL: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/6955/SPC/Modecate+ Concentrate+Injection+100mg+ml/[Accessed 2012 Jan 17]
45. Janssen-Cilag Ltd. Haldol-decanoate (haloperidol decanoate) 50 and 100mg/mL: UK summary of product characteristics [online]. Available from URL: http://www.me dicines.org.uk/EMC/medicine/904/SPC/Haldol+Decanoate/[Accessed 2012 Jan 17]
46. Sanofi-Aventis. Piportil(pipotiazine palmitate) depot 50 mg/mL solution for injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/950/SPC/Piportil+Depot+ Injection/[Accessed 2012 Jan 17]
47. Lundbeck Ltd. Clopixol(zuclopenthixol decanoate) solution for injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/EMC/medicine/21319/SPC/Clopixol+Injection+and+ Conc+Injection/[Accessed 2012 Jan 17]
48. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 Sep; 353 (12): 1209-23 (Pubitemid 41345943)
49. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry 2009 Nov; 195 (52): s63-7
50. Fleischhacker WW. Second-generation antipsychotic longacting injections: systematic review. Br J Psychiatry 2009; 195 (5 Suppl.): S29-36
51. Janssen-Cilag Ltd. Risperdal Consta (risperidone) powder and solvent for prolonged-release suspension for injection: UK summary of product characteristics [online]. Available from URL: http://www.medicines.org.uk/EMC/ medicine/9939/SPC/RISPERDAL+CONSTA+25%2c+37.5+and+50+ mg+powder+and+solvent+for+prolonged-release+suspension+ for+intramuscular+injection/[Accessed 2012 Jan 17]
52. Eli Lilly Nederland BV. Zypadhera (olanzapine pamoate) powder and solvent for prolonged release suspension for injection: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/hu man/000890/WC500054429.pdf [Accessed 2012 Jan 17]
53. Citrome L. Paliperidone palmitate: review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010; 64 (2): 216-39